THE #1 MOST USED SURFACTANT WORLDWIDE1


CUROSURF is leading the way in global market share among U.S. FDA-approved surfactants1,2

0255075100GLOBAL MARKET SHARE AMONG US FDA-APPROVED SURFACTANTS (%)CUROSURF®(poractant alfa)*Survanta®(beractant)*Infasurf®(calfactant)*88.1%7.6%4.3%

*CUROSURF is available in 94 countries.1 Infasurf is available in 21 countries.3,4 Survanta data not available. Number of countries used in varies for each surfactant.


111

Chosen by the majority of top hospitals that use surfactant1,5,6

Hospitals using CUROSURF®(poractant alfa)0255075100SHARE OF HOSPITALS (%)Neonatology Hospitals84.6%Children’s Hospitals50 Best Hospitals for NeonatologyUS News and World ReportUS Member HospitalsChildren’s Hospital Association81.2%

Based on US News and World Report’s “50 Best Hospitals for Neonatology” and Data on File, Chiesi USA, Inc., 2018.

Based on hospitals listed in the Children’s Hospital Association’s “Children’s Hospital Directory” and Data on File, Chiesi USA, Inc., 2018.

CUROSURF is intended for intratracheal use only. The administration of exogenous surfactants, including CUROSURF, can rapidly affect oxygenation and lung compliance. Therefore, infants receiving CUROSURF should receive frequent clinical and laboratory assessments so that oxygen and ventilatory support can be modified to respond to respiratory changes.

More NICUs select CUROSURF than all other surfactants combined§7,8

§The number of patients treated with each surfactant is calculated by dividing the total amount of each surfactant sold by the average amount of surfactant each patient receives. Please note that this metric only provides insight into the surfactant selected by NICUs and does not imply equivalence or superiority between or among the products for any given clinical end point.

CUROSURF is keeping pace with clinical practice

  • Safety and efficacy evaluated across 25 clinical trials, in over 5200 patients
  • Growing bibliography of clinical literature that includes over 60 published articles
  • The surfactant most widely studied with less invasive ventilation strategies
  • Continuing support dedicated to the advancement of neonatology research and the treatment of RDS

Want more information about CUROSURF and RDS in premature infants?

Gain quick access to multiple clinical studies and other resources all in one integrated library.

SEE RESOURCES
IMPORTANT SAFETY INFORMATION

CUROSURF® (poractant alfa) is intended for intratracheal use only. The administration of exogenous surfactants, including CUROSURF, can rapidly affect oxygenation and lung compliance. Therefore, infants receiving CUROSURF should receive frequent clinical and laboratory assessments so that oxygen and ventilatory support can be modified to respond to respiratory changes.

CUROSURF should only be administered by those trained and experienced in the care, resuscitation, and stabilization of preterm infants.

Transient adverse reactions associated with administration of CUROSURF include bradycardia, hypotension, endotracheal tube blockage, and oxygen desaturation. These events require stopping CUROSURF administration and taking appropriate measures to alleviate the condition. After the patient is stable, dosing may proceed with appropriate monitoring.

Pulmonary hemorrhage, a known complication of premature birth and very low birth-weight, has been reported with CUROSURF. The rates of common complications of prematurity observed in a multicenter single-dose study that enrolled infants 700–2000 g birth weight with RDS requiring mechanical ventilation and FiO2 ≥ 0.60 are as follows for CUROSURF 2.5 mL/kg (200 mg/kg) (n=78) and control (n=66; no surfactant) respectively: acquired pneumonia (17% vs. 21%), acquired septicemia (14% vs. 18%), bronchopulmonary dysplasia (18% vs. 22%), intracranial hemorrhage (51% vs. 64%), patent ductus arteriosus (60% vs. 48%), pneumothorax (21% vs. 36%) and pulmonary interstitial emphysema (21% vs. 38%).

INDICATION

CUROSURF® (poractant alfa) Intratracheal Suspension is indicated for the rescue treatment of Respiratory Distress Syndrome (RDS) in premature infants. CUROSURF reduces mortality and pneumothoraces associated with RDS.

Please see Full Prescribing Information.

References: 1. IQVIA Global Market Share. Total Year 2017. 2. IQVIA data 2018.  3. Data on File, Chiesi Farmaceutici S.p.A. and Chiesi USA, Inc., 2018. 4. US News & World Report website. https://health.usnews.com/best-hospitals/pediatric-rankings/neonatal-care. Accessed 9/25/18. 5. Children’s Hospital Association website. https://www.childrenshospitals.org/Directories/Hospital-Directory. Accessed 9/25/18. 6. IQVIA NSP CUROSURF Market. 7. IQVIA NSP CUROSURF market, September 5, 2018. 8. Premier Research Services Surfactant Dosing Summary Average Dosing for RDS + Patients, 2013.